Your browser doesn't support javascript.
loading
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt, Christoph; Dugan, Margaret; Wild, Robert; Richartz, Vanessa; Holz, Barbara; Scheel, Andreas H; Brägelmann, Johannes; Wagener-Ryczek, Svenja; Merkelbach-Bruse, Sabine; Wolf, Juergen; Buettner, Reinhard; Catanzariti, Luigi; Scheffler, Matthias; Hillmer, Axel M.
Afiliación
  • Arolt C; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Dugan M; Dracen Pharmaceuticals Inc., San Diego, California.
  • Wild R; Dracen Pharmaceuticals Inc., San Diego, California.
  • Richartz V; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Holz B; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Scheel AH; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Brägelmann J; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany; Department of Translational Genomics, University of Cologne, Faculty of Medicine and University Hospit
  • Wagener-Ryczek S; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Merkelbach-Bruse S; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Lung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Wolf J; Lung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany; Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Buettner R; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Lung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Catanzariti L; Dracen Pharmaceuticals Inc., San Diego, California.
  • Scheffler M; Lung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany; Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Hillmer AM; Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. Electronic address: ahillmer@uni-koeln.de.
J Thorac Oncol ; 18(11): 1550-1567, 2023 11.
Article en En | MEDLINE | ID: mdl-37473958
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Idioma: En Revista: J Thorac Oncol Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Idioma: En Revista: J Thorac Oncol Año: 2023 Tipo del documento: Article